Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
American Journal of Cardiovascular Drugs
Erschienen in: American Journal of Cardiovascular Drugs 2/2024

01.02.2024 | Original Research Article

Serum Cystatin C as a Risk Factor for Supratherapeutic Digoxin Concentration in Elderly Patients with Heart Failure and Chronic Kidney Disease

verfasst von: Jie-Jiu Lu, Tao-Tao Liu

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Digoxin is primarily metabolized by the kidney, and its toxicity is strongly associated with high concentrations, particularly in elderly patients. The purpose of this study was to evaluate the predictive performance of renal function biomarkers for supratherapeutic digoxin concentrations in elderly patients with heart failure (HF) and chronic kidney disease (CKD).

Methods

Data were retrospectively obtained from elderly patient with HF and CKD who received digoxin treatment from January 2022 and December 2022. Logistic regression was used to assess independent risk factors for supratherapeutic concentrations. The predictive performance of serum creatinine, serum cystatin C, and blood urea nitrogen on supratherapeutic concentrations was compared by receiver operating characteristic analysis.

Results

A total of 115 elderly patients with HF and CKD were enrolled in our study. Supratherapeutic concentrations were detected in 49 patients. Logistic regression analysis showed that estimated glomerular filtration rate calculated by serum cystatin C [eGFRCysC, odds ratio (OR): 0.962, P = 0.006], heart rate (OR: 1.024, P = 0.040), and NYHA class (OR: 3.099, P = 0.010) were independent risk factors for supratherapeutic concentration. Cutoff value for eGFRCysC between the two groups was 41 ml/min/1.73m2. Predictive performance of serum cystatin C was further improved in patients with obesity, CKD stage 4–5, and older than 75 years compared with normal weight, CKD stage 3, and aged 60–75-year-old patients.

Conclusions

Serum cystatin C is a sensitive renal function biomarker to predict supratherapeutic digoxin concentration in elderly patients with HF and CKD.
Literatur
1.
2.
Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123–33.CrossRefPubMed
3.
Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993;22(4):955–62.
4.
Devereux RB. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med. 1993;329(24):1820.PubMed
5.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239.CrossRefPubMed
6.
Moffett BS, Garner A, Zapata T, Orcutt J, Niu M, Lopez KN. Serum digoxin concentrations and clinical signs and symptoms of digoxin toxicity in the paediatric population. Cardiol Young. 2016;26(3):493–8.CrossRefPubMed
7.
Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, et al. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018;71(10):1063–74.CrossRefPubMed
8.
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10(10):933–89.
9.
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709–33.CrossRef
10.
Pontremoli R, Borghi C, Perrone FP. Renal protection in chronic heart failure: focus on sacubitril/valsartan. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):445–52.CrossRefPubMedPubMedCentral
11.
Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–52.CrossRefPubMed
12.
Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–30.CrossRefPubMed
13.
14.
Dodder NG, Tai SS, Sniegoski LT, Zhang NF, Welch MJ. Certification of creatinine in a human serum reference material by GC-MS and LC-MS. Clin Chem. 2007;53(9):1694–9.CrossRefPubMed
15.
Grubb A, Blirup-Jensen S, Lindström V, Schmidt C, Althaus H, Zegers I. First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin Chem Lab Med. 2010;48(11):1619–21.CrossRefPubMed
16.
Sae-Lim O, Doungngern T, Jaisue S, Cheewatanakornkul S, Arunmanakul P, Anutrakulchai S, et al. Prediction of serum digoxin concentration using estimated glomerular filtration rate in Thai population. Int J Gen Med. 2019;12:455–63.CrossRefPubMedPubMedCentral
17.
El-Sarnagawy GN, El Sharkawy SI, Helal NE. Predictive factors for recurrence of serious arrhythmias in patients with acute digoxin poisoning. Cardiovasc Toxicol. 2021;21(10):835–47.CrossRefPubMed
18.
Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;36(28):1831–8.CrossRefPubMed
19.
O’Riordan S, Ouldred E, Brice S, Jackson SH, Swift CG. Serum cystatin C is not a better marker of creatinine or digoxin clearance than serum creatinine. Br J Clin Pharmacol. 2002;53(4):398–402.CrossRefPubMedPubMedCentral
20.
Nakamura T, Ioroi T, Sakaeda T, Horinouchi M, Hayashi N, Saito K, et al. Serum cystatin C levels to predict serum concentration of digoxin in Japanese patients. Int J Med Sci. 2006;3(3):92–6.CrossRefPubMedPubMedCentral
21.
Hallberg P, Melhus H, Hansson LO, Larsson A. Cystatin C vs creatinine as markers of renal function in patients on digoxin treatment. Ups J Med Sci. 2004;109(3):247–53.CrossRefPubMed
22.
Garcia A, Hermida J, Tutor JC. Estimation of the glomerular filtration rate from serum creatinine and cystatin C with regard to therapeutic digoxin monitoring. J Clin Pharmacol. 2007;47(11):1450–5.CrossRefPubMed
23.
Šálek T, Vodička M, Gřiva M. Cystatin C may be better than creatinine for digoxin dosing in older adults with atrial fibrillation. J Clin Lab Anal. 2020;34(10): e23427.CrossRefPubMedPubMedCentral
24.
Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in patients with chronic kidney disease. Ren Fail. 2008;30(2):181–6.CrossRefPubMed
25.
Yassine HN, Trenchevska O, Dong Z, Bashawri Y, Koska J, Reaven PD, et al. The association of plasma cystatin C proteoforms with diabetic chronic kidney disease. Proteome Sci. 2016;14:7.CrossRefPubMedPubMedCentral
26.
27.
Deo R, Shlipak MG, Ix JH, Ali S, Schiller NB, Whooley MA. Association of cystatin C with ischemia in patients with coronary heart disease. Clin Cardiol. 2009;32(11):E18-22.CrossRefPubMedPubMedCentral
28.
Einwoegerer CF, Domingueti CP. Association between increased levels of cystatin c and the development of cardiovascular events or mortality: a systematic review and meta-analysis. Arq Bras Cardiol. 2018;111(6):796–807.PubMedPubMedCentral
29.
Vigil A, Condés E, Vigil L, Gallar P, Oliet A, Ortega O, et al. Cystatin C as a predictor of mortality and cardiovascular events in a population with chronic kidney disease. Int J Nephrol. 2014;2014: 127943.CrossRefPubMedPubMedCentral
30.
Ruan ZB, Zhu L, Yin YG, Chen GC. Cystatin C, N-terminal probrain natriuretic peptides and outcomes in acute heart failure with acute kidney injury in a 12-month follow-up: Insights into the cardiorenal syndrome. J Res Med Sci. 2014;19(5):404–9.PubMedPubMedCentral
31.
White CA, Akbari A, Allen C, Day AG, Norman PA, Holland D, et al. Simultaneous glomerular filtration rate determination using inulin, iohexol, and (99m)Tc-DTPA demonstrates the need for customized measurement protocols. Kidney Int. 2021;99(4):957–66.CrossRefPubMed
32.
Heymsfield SB, Arteaga C, McManus C, Smith J, Moffitt S. Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr. 1983;37(3):478–94.CrossRefPubMed
33.
34.
Wilkinson DJ, Piasecki M, Atherton PJ. The age-related loss of skeletal muscle mass and function: measurement and physiology of muscle fibre atrophy and muscle fibre loss in humans. Ageing Res Rev. 2018;47:123–32.CrossRefPubMedPubMedCentral
35.
Ivey-Miranda JB, Inker LA, Griffin M, Rao V, Maulion C, Turner JM, et al. Cystatin c and muscle mass in patients with heart failure. J Card Fail. 2021;27(1):48–56.CrossRefPubMed
36.
Nankivell BJ, Nankivell LFJ, Elder GJ, Gruenewald SM. How unmeasured muscle mass affects estimated GFR and diagnostic inaccuracy. EClinicalMedicine. 2020;29–30: 100662.CrossRefPubMedPubMedCentral
37.
Soveri I, Berg UB, Björk J, Elinder CG, Grubb A, Mejare I, et al. Measuring GFR: a systematic review. Am J Kidney Dis. 2014;64(3):411–24.CrossRefPubMed
38.
39.
Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40(2):221–6.CrossRefPubMed
Metadaten
Titel
Serum Cystatin C as a Risk Factor for Supratherapeutic Digoxin Concentration in Elderly Patients with Heart Failure and Chronic Kidney Disease
verfasst von
Jie-Jiu Lu
Tao-Tao Liu
Publikationsdatum
01.02.2024
Verlag
Springer International Publishing
Erschienen in
American Journal of Cardiovascular Drugs / Ausgabe 2/2024
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI
https://doi.org/10.1007/s40256-024-00629-5

Weitere Artikel der Ausgabe 2/2024

American Journal of Cardiovascular Drugs 2/2024 Zur Ausgabe

Letter to the Editor

Comment on: “Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”

Review Article

The Rationale for Using Fixed-Dose Combination Therapy in the Management of Hypertension in Colombia: A Narrative Review

Systematic Review

Comparative Effectiveness and Safety of Direct Oral Anticoagulants Compared with Warfarin in Patients with Low Bodyweight who have Atrial Fibrillation: A Systematic Review and Meta-analysis

Review Article

Management of Hypertension in the Asia-Pacific Region: A Structured Review

Original Research Article

Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea

Letter to the Editor

Author’s Reply to Kow et al.: “Comparison of Clinical Outcomes between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen